SERA (Sera Prognostics) Total Liabilities: $25.92 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SERA Sera Prognostics Inc SERA
69 GF Score
Price $2.05
GF Value $1.83
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Sera Prognostics Total Liabilities?

Sera Prognostics SERA -5.96% 69 Total Liabilities is $25.92 Mil as of Mar. 2026. GuruFocus rates SERA with a GF Score™ of 69/100 and a GF Value™ of $1.83 (Modestly Overvalued). The stock has 5 warning signs investors should review.

Sera Prognostics's Total Liabilities for the quarter that ended in Mar. 2026 was $25.92 Mil.

Sera Prognostics's quarterly Total Liabilities increased from Sep. 2025 ($25.94 Mil) to Dec. 2025 ($26.53 Mil) but then declined from Dec. 2025 ($26.53 Mil) to Mar. 2026 ($25.92 Mil).

Sera Prognostics's annual Total Liabilities declined from Dec. 2023 ($25.28 Mil) to Dec. 2024 ($24.77 Mil) but then increased from Dec. 2024 ($24.77 Mil) to Dec. 2025 ($26.53 Mil).

Sera Prognostics Total Liabilities Historical Data

* Premium members only.

The historical data trend for Sera Prognostics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sera Prognostics Total Liabilities Chart

Sera Prognostics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial 8.47 17.39 25.28 24.77 26.53

Sera Prognostics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 23.40 23.60 25.94 26.53 25.92
SERA
69GF Score
Sera Prognostics Inc SERA
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sera Prognostics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Sera Prognostics's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=24.188+(2.337+-4.4408920985006E-16
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=26.53

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=101.933-75.408
=26.53

Sera Prognostics's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=23.419+(2.505+-8.8817841970013E-16
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=25.92

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=93.544-67.62
=25.92

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $25.92 Mil mean?
Sera Prognostics (SERA) has a Total Liabilities of $25.92 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Sera Prognostics and its competitors.
Is Sera Prognostics' Total Liabilities too high?
Sera Prognostics' current Total Liabilities is $25.92 Mil. Overall, Sera Prognostics has a GF Score™ of 69/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sera Prognostics' Total Liabilities compare to LNSR and ECOR?
Sera Prognostics' Total Liabilities of $25.92 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Medical Devices & Instruments company?
A good Total Liabilities depends on the Medical Devices & Instruments industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Sera Prognostics and its competitors. Sera Prognostics's current Total Liabilities is $25.92 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sera Prognostics stock overvalued right now?
Based on GuruFocus' analysis, Sera Prognostics (SERA) is currently considered Modestly Overvalued. The stock's GF Value™ is $1.83, compared to a current price of $2.05 — trading 12% above its estimated fair value. The current Total Liabilities is $25.92 Mil. Sera Prognostics' overall GF Score™ is 69/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Sera Prognostics (SERA), the current Total Liabilities is $25.92 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sera Prognostics (SERA) Overvalued in 2026?

Based on GuruFocus' analysis, Sera Prognostics stock appears to be overvalued. The current stock price of $2.05 is trading 12% above its estimated GF Value™ of $1.83. GuruFocus considers Sera Prognostics to be Modestly Overvalued.

Key valuation signals for SERA:

  • Total Liabilities: $25.92 Mil
  • GF Value™: $1.83 vs. price of $2.05 (12% above fair value)
  • GF Score™: 69/100 with 5 warning signs

No single metric tells the full story. See the SERA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sera Prognostics Business Description

Address 2749 East Parleys Way, Suite 200, Salt Lake City, UT, USA, 84109
Sera Prognostics Inc is a health diagnostic company. It is a women's health company utilizing the proprietary proteomics and bioinformatics platform, and data resources to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.
69GF Score

Get the complete analysis for SERA

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.05
Price
$1.83
GF Value